Breaking News Instant updates and real-time market news.

XENT

Intersect ENT

$28.78

0.04 (0.14%)

10:06
10/02/18
10/02
10:06
10/02/18
10:06

Intersect ENT strength attributed to Sinuva appearance on Anthem drug list

Intersect ENT's (XENT) Sinuva nasal implant appears on Anthem's (ANTM) national drug list, which is being pointed to as the reason for the stock's early strength, according to contacts. Intersect ENT shares are up about 5% to $30.08 in early trading. Reference Link

  • 27

    Nov

XENT Intersect ENT
$28.78

0.04 (0.14%)

05/07/18
PIPR
05/07/18
NO CHANGE
Target $45
PIPR
Overweight
Piper says CMS made error, buy shares of Intersect ENT
This morning on the Centers for Medicare & Medicaid Services website, the agency, in a preliminary assessment, assigned Intersect ENT's Sinuva a J-Code that is based on a CPT code for its Propel technology, which will be deleted at the beginning of next year, Piper Jaffray analyst Matt O'Brien tells investors in a research note. This appears to be an error on the part of CMS, the analyst adds. He fully anticipates it will be corrected in the final rule, which is expected to come out in November. O'Brien recommends investors take advantage of this morning's pullback to start or build positions in Intersect ENT. He doubts any clinicians would become concerned about the incorrect regulatory coding and does not anticipate any type of impact to the launch of Sinuva as a result. The analyst has an Overweight rating on Intersect ENT with a $45 price target. The stock in morning trading is down 6% to $39.15.
05/11/18
PIPR
05/11/18
NO CHANGE
Target $45
PIPR
Overweight
Intersect ENT selloff this week a buying opportunity, says Piper Jaffray
After hosting investor meetings with Intersect ENT management, Piper Jaffray analyst Matt O'Brien says J-code risk is overstated. Management spent a considerable amount of time discussing the preliminary J-Code ruling for Sinuva that came out earlier this week and noted that this was a clear clerical error, O'Brien tells investors in a research note. The analyst thinks the Sinuva launch is progressing well and that Intersect ENT's base business also has "significant room for growth." He believes investors should take advantage of the pullback earlier this week to start positions in the shares. O'Brien has an Overweight rating on Intersect ENT with a $45 price target.
08/01/18
PIPR
08/01/18
NO CHANGE
Target $40
PIPR
Overweight
Intersect ENT price target lowered to $40 from $45 at Piper Jaffray
Piper Jaffray analyst Matt O'Brien lowered his price target for Intersect ENT to $40 from $45 after the company missed Q2 revenues and reduced full year 2018 guidance. Essentially, the disappointment in the quarter and for the outlook this year is the company's key new SINUVA product, which is ramping slower than expected due to reimbursement processing issues, he notes. Although this is disappointing and there is no guarantee that more road bumps in the launch will not pop up, the analyst still believes utilization will be quite strong and growth in 2019 and beyond will be among the best in small cap med tech. O'Brien reiterates an Overweight rating on the shares.
09/18/18
PIPR
09/18/18
NO CHANGE
Target $40
PIPR
Overweight
Intersect risk/reward favorable into reimbursement decision, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien see as favorable risk/reward for Intersect ENT shares ahead of the late November reimbursement decision for Sinuva. It is likely that Sinuva will get the J-code code either this year or next year, which can provide upside to 2018 and 2019 estimates, O'Brien tells investors in a research note. Further, not getting the code will merely represent a timing issue as clinicians will just need to get comfortable with reimbursement, the analyst adds. He believes that Sinuva's value is currently being mispriced regardless of the outcome and recommends shares of Intersect ENT with an Overweight rating and $40 price target.

TODAY'S FREE FLY STORIES

CSBR

Champions Oncology

$12.10

-0.61 (-4.80%)

15:00
10/22/18
10/22
15:00
10/22/18
15:00
Conference/Events
Champions Oncology management to meet with Craig-Hallum »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 15

    Nov

SCG

Scana

$36.09

-4.8 (-11.74%)

, D

Dominion

$73.39

-0.135 (-0.18%)

14:57
10/22/18
10/22
14:57
10/22/18
14:57
Periodicals
SC senator: Law on nuclear construction to be deemed unconstitutional, CBJ says »

South Carolina state…

SCG

Scana

$36.09

-4.8 (-11.74%)

D

Dominion

$73.39

-0.135 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

  • 11

    Nov

  • 11

    Nov

SCG

Scana

$36.43

-4.46 (-10.91%)

, D

Dominion

$73.29

-0.235 (-0.32%)

14:55
10/22/18
10/22
14:55
10/22/18
14:55
Periodicals
Breaking Periodicals news story on Scana, Dominion »

Dominion declines comment…

SCG

Scana

$36.43

-4.46 (-10.91%)

D

Dominion

$73.29

-0.235 (-0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

  • 11

    Nov

  • 11

    Nov

SYMC

Symantec

$19.73

0.06 (0.31%)

14:50
10/22/18
10/22
14:50
10/22/18
14:50
Options
Sweep buyer of Symantec call options »

Sweep buyer of Symantec…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 01

    Nov

  • 06

    Dec

AMTD

TD Ameritrade

$50.05

-0.44 (-0.87%)

14:49
10/22/18
10/22
14:49
10/22/18
14:49
Options
TD Ameritrade options imply 5.8% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

MRBK

Meridian Bank

$17.01

(0.00%)

14:42
10/22/18
10/22
14:42
10/22/18
14:42
Hot Stocks
Meridian Bank names Randy J. McGarry chief information officer »

Randy J. McGarry has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KKR

KKR

$24.01

-0.21 (-0.87%)

14:35
10/22/18
10/22
14:35
10/22/18
14:35
Options
KKR put volume heavy and directionally bearish »

Bearish flow noted in KKR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

AU

AngloGold

$9.86

0.05 (0.51%)

14:34
10/22/18
10/22
14:34
10/22/18
14:34
Hot Stocks
AngloGold says Kibali Gold Mine seen delivering record performance in Q3 »

AngloGold Ashanti reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$155.28

1.33 (0.86%)

, SNAP

Snap

$6.79

-0.03 (-0.44%)

14:32
10/22/18
10/22
14:32
10/22/18
14:32
OnTheFly
Piper's teen survey bodes well for Instagram, Prime as Apple remains dominant »

Piper Jaffray analyst…

FB

Facebook

$155.28

1.33 (0.86%)

SNAP

Snap

$6.79

-0.03 (-0.44%)

AAPL

Apple

$220.90

1.62 (0.74%)

AMZN

Amazon.com

$1,784.13

20.22 (1.15%)

WMT

Walmart

$97.13

-0.02 (-0.02%)

SSNLF

Samsung

$0.00

(0.00%)

ATVI

Activision Blizzard

$69.71

-0.04 (-0.06%)

EA

Electronic Arts

$102.05

-0.02 (-0.02%)

TTWO

Take-Two

$120.88

-1.62 (-1.32%)

GOOG

Alphabet

$1,103.00

6.59 (0.60%)

GOOGL

Alphabet Class A

$1,112.00

7.34 (0.66%)

ZNGA

Zynga

$4.02

0.01 (0.25%)

GLUU

Glu Mobile

$5.94

0.09 (1.54%)

VFC

VF Corp.

$77.53

-0.21 (-0.27%)

ADDYY

Adidas

$0.00

(0.00%)

LULU

Lululemon

$139.75

2.99 (2.19%)

CROX

Crocs

$19.81

1.32 (7.14%)

SBUX

Starbucks

$58.85

0.22 (0.38%)

CMG

Chipotle

$430.22

1.13 (0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 01

    Nov

  • 06

    Nov

  • 07

    Nov

  • 08

    Nov

  • 15

    Nov

  • 13

    Dec

  • 03

    Mar

FLXN

Flexion

$16.03

-2.93 (-15.45%)

14:29
10/22/18
10/22
14:29
10/22/18
14:29
Recommendations
Flexion analyst commentary  »

Flexion 'very…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EEM

iShares MSCI Emerging Markets ETF

$40.06

0.37 (0.93%)

14:25
10/22/18
10/22
14:25
10/22/18
14:25
Technical Analysis
Technical Take: iShares MSCI Emerging Markets ETF has active bullish pattern »

There is an active double…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PENN

Penn National

$27.02

-1.14 (-4.05%)

14:25
10/22/18
10/22
14:25
10/22/18
14:25
Options
Penn National call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

MCD

McDonald's

$166.85

-0.6 (-0.36%)

14:24
10/22/18
10/22
14:24
10/22/18
14:24
Earnings
Fly Intel: What to watch in McDonald's earnings report »

McDonald's (MCD) is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

STZ

Constellation Brands

$221.76

-1.22 (-0.55%)

, STZ.B

Constellation Brands; also tag STZ

$225.00

-3.45 (-1.51%)

14:22
10/22/18
10/22
14:22
10/22/18
14:22
Periodicals
Constellation Brands looks to sell some U.S. wine brands, Reuters says »

Constellation Brands is…

STZ

Constellation Brands

$221.76

-1.22 (-0.55%)

STZ.B

Constellation Brands; also tag STZ

$225.00

-3.45 (-1.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

BLMN

Bloomin' Brands

$19.85

0.28 (1.43%)

14:20
10/22/18
10/22
14:20
10/22/18
14:20
Hot Stocks
Bloomin' Brands says has had seven discussions with Barington since March 2017 »

Bloomin' Brands, in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
10/22/18
10/22
14:17
10/22/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
10/22/18
10/22
14:16
10/22/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:15
10/22/18
10/22
14:15
10/22/18
14:15
Conference/Events
RBC Capital Israeli gas & energy analyst to hold group breakfast meeting »

Israeli Gas & Energy…

14:15
10/22/18
10/22
14:15
10/22/18
14:15
General news
Oil Action: NYMEX crude »

Oil Action: NYMEX crude…

STZ

Constellation Brands

$221.31

-1.67 (-0.75%)

, STZ.B

Constellation Brands; also tag STZ

$225.00

-3.45 (-1.51%)

14:07
10/22/18
10/22
14:07
10/22/18
14:07
Periodicals
Breaking Periodicals news story on Constellation Brands, Constellation Brands; also tag STZ »

Constellation Brands…

STZ

Constellation Brands

$221.31

-1.67 (-0.75%)

STZ.B

Constellation Brands; also tag STZ

$225.00

-3.45 (-1.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

YNDX

Yandex

$27.71

0.29 (1.06%)

, GOOG

Alphabet

$1,102.24

5.83 (0.53%)

14:06
10/22/18
10/22
14:06
10/22/18
14:06
Periodicals
Russia proposes to limit foreign ownership in news aggregators, Reuters reports »

The government is…

YNDX

Yandex

$27.71

0.29 (1.06%)

GOOG

Alphabet

$1,102.24

5.83 (0.53%)

GOOGL

Alphabet Class A

$1,111.16

6.5 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 29

    Oct

  • 07

    Nov

  • 03

    Mar

DB

Deutsche Bank

$10.74

-0.185 (-1.69%)

14:05
10/22/18
10/22
14:05
10/22/18
14:05
Options
Deutsche Bank call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$8.44

0.085 (1.02%)

14:04
10/22/18
10/22
14:04
10/22/18
14:04
Hot Stocks
Ford expanding test of autonomous vehicles to Washington, D.C. »

In an opinion editorial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 13

    Dec

ZION

Zions Bancorp

$45.92

-1.05 (-2.24%)

13:55
10/22/18
10/22
13:55
10/22/18
13:55
Options
Zions Bancorp put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

BHGE

Baker Hughes

$29.68

-0.25 (-0.84%)

13:45
10/22/18
10/22
13:45
10/22/18
13:45
Options
Baker Hughes call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.